Palvella Therapeutics Completes $45 Million Series C Financing

By

Palvella Therapeutics Completes $45 Million Series C Financing
Investor Syndicate Comprised of Leading Biotech Investors  

Proceeds to Accelerate  Pipeline of Rare Disease Therapies, Including Late-Stage Programs in Pachyonychia Congenita and Gorlin Syndrome  

Top-Line Data Expected in Q4 2020 from Phase 2/3 Pivotal Study for Fast Track-Designated Lead Program Pachyonychia Congenita    

See more here

Comments are closed.